0001213900-22-007573.txt : 20220214 0001213900-22-007573.hdr.sgml : 20220214 20220214164200 ACCESSION NUMBER: 0001213900-22-007573 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220214 DATE AS OF CHANGE: 20220214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Augmedix, Inc. CENTRAL INDEX KEY: 0001769804 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 833299164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-91688 FILM NUMBER: 22633489 BUSINESS ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISC STATE: CA ZIP: 94104 BUSINESS PHONE: 561-989-2208 MAIL ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISC STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Malo Holdings Corp DATE OF NAME CHANGE: 20190305 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Tompkins Mark N. CENTRAL INDEX KEY: 0001455971 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: APP. 1, VIA GUIDINO 23 CITY: LUGANO-PARADISO STATE: V8 ZIP: 6900 SC 13G 1 ea155514-13gmark_augmedix.htm SCHEDULE 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Schedule 13G

Under the Securities Exchange Act of 1934

 

Augmedix, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

05105P107

(CUSIP Number)

 

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐ Rule 13d-1(b)

 Rule 13d-1(c)

☒ Rule 13d-1(d)

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 05105P107

 

1.

Names of reporting persons:

 

Mark N. Tompkins

2.

Check the appropriate box if a member of a group (see instructions)

 

(a) ☐     

(b) ☐

3.

SEC use only

 

4.

Citizenship or place of organization:

 

Canada

Number of
shares
beneficially
owned by each
reporting
person with
5.

Sole voting power

 

1,935,120

6.

Shared voting power

N/A

7.

Sole dispositive power

 

1,935,120

8.

Shared dispositive power

N/A

9.

Aggregate amount beneficially owned by each reporting person

 

1,935,120

10. 

Check if the aggregate amount in row (9) excludes certain shares (see instructions)

 

11. 

Percent of class represented by amount in row (9)

 

5.2%(1)

12. 

Type of reporting person (see instructions)

 

IN

 

(1)Based on 37,158,404 shares of Common Stock of the Issuer issued and outstanding as of November 1, 2021.

 

Page 2  of 5 pages

 

 

Item 1.

 

(a) Name of issuer: Augmedix, Inc.
     
(b) Address of issuer’s principal executive offices: 111 Sutter Street, Suite 1300, San Francisco, CA, 94104

 

Item 2.

 

(a) Name of person filing: Mark N. Tompkins
     
(b) Address of principal business office or, if none, residence:

Apt. 1, Via Guidino 23

6900 Lugano-Paradiso, Switzerland

     
(c) Citizenship: Canada
     
(d) Title of class of securities: Common Stock, par value $0.0001 per share
     
(e) CUSIP number: 05105P107

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
(b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
(c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
(d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
(e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
(f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
(g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
     
(h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
(j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
     
(k) Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 

Page 3  of 5 pages

 

 

Item 4. Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a) Amount beneficially owned: 1,935,120
     
(b) Percent of class: 5.2%(1)
     
(c) Number of shares as to which the
person has:
 

 

  (i) Sole power to vote or to direct the vote. 1,935,120
       
  (ii) Shared power to vote or to direct the vote. N/A
       
  (iii) Sole power to dispose or to direct the disposition of. 1,935,120
       
  (iv) Shared power to dispose or to direct the disposition of. N/A

 

Item 5. Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group

 

Not applicable.

 

Item 9. Notice of Dissolution of Group

 

Not applicable.

 

Item 10. Certification

 

Not applicable.

 

(1)Based on 37,158,404 shares of Common Stock of the Issuer issued and outstanding as of November 1, 2021.

 

Page 4  of 5 pages

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  Dated: February 14, 2022
   
  /s/ Mark N. Tompkins
  Signature
   
  Name: Mark N. Tompkins

 

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001)

 

 

Page 5 of 5 pages